

Albert Y Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7334255/publications.pdf>

Version: 2024-02-01

64
papers

10,781
citations

94433

37
h-index

114465

63
g-index

67
all docs

67
docs citations

67
times ranked

6564
citing authors

#	ARTICLE	IF	CITATIONS
1	Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. <i>New England Journal of Medicine</i> , 2010, 363, 2587-2599.	27.0	4,268
2	Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 820-829.	9.1	1,039
3	Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men. <i>Science Translational Medicine</i> , 2012, 4, 151ra125.	12.4	807
4	Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services. <i>JAMA Internal Medicine</i> , 2016, 176, 75.	5.1	535
5	Early Experiences Implementing Pre-exposure Prophylaxis (PrEP) for HIV Prevention in San Francisco. <i>PLoS Medicine</i> , 2014, 11, e1001613.	8.4	213
6	No Evidence of Sexual Risk Compensation in the iPrEx Trial of Daily Oral HIV Preexposure Prophylaxis. <i>PLoS ONE</i> , 2013, 8, e81997.	2.5	193
7	Limited Knowledge and Use of HIV Post- and Pre-Exposure Prophylaxis Among Gay and Bisexual Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 241-247.	2.1	188
8	HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. <i>PLoS Medicine</i> , 2017, 14, e1002417.	8.4	186
9	Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	182
10	High Interest in Preexposure Prophylaxis Among Men Who Have Sex With Men at Risk for HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 439-448.	2.1	171
11	Randomized Trial of Clinical Safety of Daily Oral Tenofovir Disoproxil Fumarate Among HIV-Uninfected Men Who Have Sex With Men in the United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 79-86.	2.1	158
12	Bone Mineral Density in HIV-Negative Men Participating in a Tenofovir Pre-Exposure Prophylaxis Randomized Clinical Trial in San Francisco. <i>PLoS ONE</i> , 2011, 6, e23688.	2.5	144
13	Preexposure Prophylaxis for HIV Prevention. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, S122-S129.	2.1	139
14	Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Clinical Infectious Diseases</i> , 2015, 61, 572-580.	5.8	132
15	Sexual Behavior, Risk Compensation, and HIV Prevention Strategies Among Participants in the San Francisco PrEP Demonstration Project: A Qualitative Analysis of Counseling Notes. <i>AIDS and Behavior</i> , 2016, 20, 1461-1469.	2.7	131
16	HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 468-475.	9.1	128
17	Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. <i>PLoS Medicine</i> , 2018, 15, e1002690.	8.4	126
18	Strong Relationship between Oral Dose and Tenofovir Hair Levels in a Randomized Trial: Hair as a Potential Adherence Measure for Pre-Exposure Prophylaxis (PrEP). <i>PLoS ONE</i> , 2014, 9, e83736.	2.5	125

#	ARTICLE	IF	CITATIONS
19	Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. <i>Aids</i> , 2014, 28, 851-859.	2.2	123
20	Sexual Risk Behavior Among HIV-Uninfected Men Who Have Sex With Men Participating in a Tenofovir Preexposure Prophylaxis Randomized Trial in the United States. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 64, 87-94.	2.1	118
21	Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. <i>Lancet HIV</i> , 2020, 7, e472-e481.	4.7	97
22	Randomized Controlled Trial of a Mobile Health Intervention to Promote Retention and Adherence to Preexposure Prophylaxis Among Young People at Risk for Human Immunodeficiency Virus: The EPIC Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 2010-2017.	5.8	96
23	Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States. <i>Clinical Infectious Diseases</i> , 2018, 66, 213-219.	5.8	82
24	Participant Experiences and Facilitators and Barriers to Pill Use Among Men Who Have Sex with Men in the iPrEx Pre-Exposure Prophylaxis Trial in San Francisco. <i>AIDS Patient Care and STDs</i> , 2013, 27, 560-566.	2.5	76
25	Successful Implementation of HIV Preexposure Prophylaxis: Lessons Learned From Three Clinical Settings. <i>Current HIV/AIDS Reports</i> , 2016, 13, 116-124.	3.1	76
26	Addressing Gaps in HIV Preexposure Prophylaxis Care to Reduce Racial Disparities in HIV Incidence in the United States. <i>American Journal of Epidemiology</i> , 2019, 188, 743-752.	3.4	76
27	Supporting Study Product Use and Accuracy in Self-Report in the iPrEx Study: Next Step Counseling and Neutral Assessment. <i>AIDS and Behavior</i> , 2012, 16, 1243-1259.	2.7	71
28	The potential effect of COVID-19-related disruptions on HIV incidence and HIV-related mortality among men who have sex with men in the USA: a modelling study. <i>Lancet HIV</i> , 2021, 8, e206-e215.	4.7	70
29	Healthcare Access and PrEP Continuation in San Francisco and Miami After the US PrEP Demo Project. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 74, 531-538.	2.1	68
30	Preexposure Prophylaxis for HIV. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 863.	7.4	66
31	Patterns and Correlates of PrEP Drug Detection Among MSM and Transgender Women in the Global iPrEx Study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 67, 528-537.	2.1	63
32	Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring. <i>Journal of Infectious Diseases</i> , 2015, 212, 1402-1406.	4.0	62
33	Age, Race/Ethnicity, and Behavioral Risk Factors Associated With Per Contact Risk of HIV Infection Among Men Who Have Sex With Men in the United States. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 65, 115-121.	2.1	60
34	Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 778-783.	1.1	52
35	Missed Visits Associated With Future Preexposure Prophylaxis (PrEP) Discontinuation Among PrEP Users in a Municipal Primary Care Health Network. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz101.	0.9	49
36	Developing a Mobile App (LYNX) to Support Linkage to HIV/Sexually Transmitted Infection Testing and Pre-Exposure Prophylaxis for Young Men Who Have Sex With Men: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2019, 8, e10659.	1.0	46

#	ARTICLE	IF	CITATIONS
37	MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel. <i>Clinical Infectious Diseases</i> , 2017, 64, ciw832.	5.8	42
38	Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077. <i>AIDS and Behavior</i> , 2020, 24, 2520-2531.	2.7	41
39	Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension. <i>Clinical Infectious Diseases</i> , 2016, 62, 1172-1177.	5.8	40
40	Missed opportunities to prevent HIV infections among pre-exposure prophylaxis users: a population-based mixed methods study, San Francisco, United States. <i>Journal of the International AIDS Society</i> , 2020, 23, e25472.	3.0	40
41	Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077. <i>Clinical Infectious Diseases</i> , 2020, 70, 319-322.	5.8	31
42	DOT Diary: Developing a Novel Mobile App Using Artificial Intelligence and an Electronic Sexual Diary to Measure and Support PrEP Adherence Among Young Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2021, 25, 1001-1012.	2.7	29
43	Body/Selves and Beyond: Men's Narratives of Sexual Behavior on PrEP. <i>Medical Anthropology: Cross Cultural Studies in Health and Illness</i> , 2018, 37, 387-400.	1.2	27
44	Provider Adherence to Pre-exposure Prophylaxis Monitoring Guidelines in a Large Primary Care Network. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy099.	0.9	26
45	Targeting Pre-Exposure Prophylaxis Among Men Who Have Sex With Men in the United States and Peru. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, 119-125.	2.1	25
46	The Safety of Tenofovir Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 281-286.	2.1	25
47	High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women. <i>PLoS ONE</i> , 2017, 12, e0181607.	2.5	25
48	A Comparison of Hospitalized Patients With Heart Failure and Cancer Referred to Palliative Care. <i>JAMA Network Open</i> , 2020, 3, e200020.	5.9	25
49	Pre-exposure prophylaxis for HIV prevention preferences among young adult African American men who have sex with men. <i>PLoS ONE</i> , 2018, 13, e0209484.	2.5	23
50	Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in Delivery. <i>Current Treatment Options in Infectious Diseases</i> , 2015, 7, 101-112.	1.9	22
51	HIV self-testing and STI self-collection via mobile apps: experiences from two pilot randomized controlled trials of young men who have sex with men. <i>MHealth</i> , 2021, 7, 26-26.	1.6	22
52	Palliative Care in Heart Failure: What Triggers Specialist Consultation?. <i>Progress in Cardiovascular Diseases</i> , 2017, 60, 215-225.	3.1	19
53	Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial. <i>PLoS ONE</i> , 2018, 13, e0190118.	2.5	18
54	Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men. <i>AIDS and Behavior</i> , 2017, 21, 3336-3345.	2.7	16

#	ARTICLE	IF	CITATIONS
55	Phase 1 pharmacokinetics and safety study of extended duration dapivirine vaginal rings in the United States. <i>Journal of the International AIDS Society</i> , 2021, 24, e25747.	3.0	15
56	Development and Validation of the Personalized Sexual Health Promotion (SexPro) HIV Risk Prediction Model for Men Who Have Sex with Men in the United States. <i>AIDS and Behavior</i> , 2020, 24, 274-283.	2.7	14
57	Adapting technology-based HIV prevention and care interventions for youth: lessons learned across five U.S. Adolescent Trials Network studies. <i>MHealth</i> , 2021, 7, 21-21.	1.6	12
58	Acceptability and Preference for 3-Month Versus 1-Month Vaginal Rings for HIV-1 Risk Reduction Among Participants in a Phase 1 Trial. <i>Journal of Women's Health</i> , 2022, 31, 1029-1039.	3.3	7
59	The case for prescribing PrEP in community mental health settings. <i>Lancet HIV</i> , the, 2021, 8, e237-e244.	4.7	5
60	Integrated Next Step Counseling for Sexual Health Promotion and Medication Adherence for Individuals Using Pre-exposure Prophylaxis. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A159-A159.	1.1	4
61	The importance of PrEP persistence in preventing HIV infections on PrEP. <i>Journal of the International AIDS Society</i> , 2020, 23, e25578.	3.0	4
62	Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 226-239.	4.9	2
63	Assessing the use of surveillance data to estimate the impact of prevention interventions on HIV incidence in cluster-randomized controlled trials. <i>Epidemics</i> , 2020, 33, 100423.	3.0	1
64	Users' Preferred Characteristics of Vaginal Rings for HIV Prevention: A Qualitative Analysis of Two Phase I Trials. <i>AIDS Research and Human Retroviruses</i> , 2021, , .	1.1	1